CTCF: A promising drug target and biomarker for the treatment of transcribed repressor gene-expression disorders

Target Name: CTCF

NCBI ID: G10664

CTCF

CTCF: A promising drug target and biomarker for the treatment of transcribed repressor gene-expression disorders

Transcribed repressor genes (TRGs) are a class of gene that play a crucial role in regulating gene expression in various organisms. These genes are often involved in the regulation of cellular processes such as cell growth, differentiation, and reproduction. TRGs can also play a key role in the development and progression of diseases such as cancer. CTCF, or transcriptional repressor CTCF (ISO Form 2), is one of the most well-known TRGs. In this article, we will discuss the biology of CTCF, its potential as a drug target, and its potential as a biomarker for the treatment of transcribed repressor gene-expression disorders.

Biochemistry and function

CTCF is a non-coding RNA molecule that is approximately 200 amino acids long. It is expressed in various tissues and cells throughout the body and plays a critical role in the regulation of gene expression. CTCF is composed of two main subunits: an alpha subunit and a beta subunit. The alpha subunit is responsible for the formation of a complex with the beta subunit, which interacts with the target RNA molecule. This interaction between CTCF and its target RNA molecule is known as the CTCF-RNA interaction.

CTCF is highly expressed in various tissues, including the brain, heart, and testes. It is also highly expressed in cancer cells, which suggests that it may be involved in the regulation of cancer cell growth and progression.

Potential as a drug target

CTCF has been identified as a potential drug target due to its involvement in the regulation of gene expression. Many studies have shown that inhibiting CTCF can lead to the downregulation of target RNA molecules, which can lead to the inhibition of gene expression. This suggests that CTCF may be a useful target for the treatment of transcribed repressor gene-expression disorders.

One of the most promising strategies for targeting CTCF is the use of small molecules. Many small molecules have been shown to inhibit the activity of CTCF, including inhibitors that target the CTCF-RNA interaction. These inhibitors have been shown to be effective in treating a variety of transcribed repressor gene-expression disorders, including cancer.

In addition to small molecules, another approach to targeting CTCF is the use of RNA interference (RNAi) technology. RNAi allows researchers to introduce small interfering RNA (siRNA) into cells, which can specifically target and knockdown CTCF mRNA levels. This approach has been shown to be effective in treating a variety of transcribed repressor gene-expression disorders, including cancer.

Potential as a biomarker

CTCF has also been shown to be a potential biomarker for the treatment of transcribed repressor gene-expression disorders. The downregulation of CTCF target RNA molecules has been shown to be a common event in the development and progression of diseases, including cancer. Therefore, measuring the levels of CTCF target RNA molecules may be an effective biomarker for the treatment of these disorders.

In addition to measuring the levels of CTCF target RNA molecules, there are also several other approaches that can be used to assess the effectiveness of a drug or treatment for the treatment of transcribed repressor gene-expression disorders. These include measuring the levels of target RNA molecules, measuring the expression of target genes, and measuring the impact on disease progression.

Conclusion

CTCF is a non-coding RNA molecule that plays a critical role in the regulation of gene expression. Its downregulation has been shown to be a common event in the development and progression of diseases, including cancer. As a result, CTCF has emerged as a promising drug target and biomarker for the treatment of transcribed repressor gene-expression disorders. Further research is needed to fully understand the biology of CTCF and its potential as a drug

Protein Name: CCCTC-binding Factor

Functions: Chromatin binding factor that binds to DNA sequence specific sites. Involved in transcriptional regulation by binding to chromatin insulators and preventing interaction between promoter and nearby enhancers and silencers. Acts as transcriptional repressor binding to promoters of vertebrate MYC gene and BAG1 gene. Also binds to the PLK and PIM1 promoters. Acts as a transcriptional activator of APP. Regulates APOA1/C3/A4/A5 gene cluster and controls MHC class II gene expression. Plays an essential role in oocyte and preimplantation embryo development by activating or repressing transcription. Seems to act as tumor suppressor. Plays a critical role in the epigenetic regulation. Participates in the allele-specific gene expression at the imprinted IGF2/H19 gene locus. On the maternal allele, binding within the H19 imprinting control region (ICR) mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to IGF2. Plays a critical role in gene silencing over considerable distances in the genome. Preferentially interacts with unmethylated DNA, preventing spreading of CpG methylation and maintaining methylation-free zones. Inversely, binding to target sites is prevented by CpG methylation. Plays an important role in chromatin remodeling. Can dimerize when it is bound to different DNA sequences, mediating long-range chromatin looping. Mediates interchromosomal association between IGF2/H19 and WSB1/NF1 and may direct distant DNA segments to a common transcription factory. Causes local loss of histone acetylation and gain of histone methylation in the beta-globin locus, without affecting transcription. When bound to chromatin, it provides an anchor point for nucleosomes positioning. Seems to be essential for homologous X-chromosome pairing. May participate with Tsix in establishing a regulatable epigenetic switch for X chromosome inactivation. May play a role in preventing the propagation of stable methylation at the escape genes from X- inactivation. Involved in sister chromatid cohesion. Associates with both centromeres and chromosomal arms during metaphase and required for cohesin localization to CTCF sites. Regulates asynchronous replication of IGF2/H19. Plays a role in the recruitment of CENPE to the pericentromeric/centromeric regions of the chromosome during mitosis (PubMed:26321640)

The "CTCF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTCF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets